Recombinant Human TWEAK/TNFSF12 Protein, CF 1090-TW-025/CF from R&D Systems, a Bio-Techne Brand

Product Specs
ItemRecombinant Human TWEAK/TNFSF12 Protein, CF
CompanyR&D Systems, a Bio-Techne Brand
Price $449.00Supplier Page View Company Product Page
Catalog Number1090-TW-025/CF
SpeciesHuman
Source/Expression SystemE. coli-derived Recombinant Human TWEAK/TNFSF12 Protein, CF
Size25 ug
FormatLyophilized from a 0.2 µm filtered solution in PBS
Molecule NameTWEAK/TNFSF12
NCBI Full Gene NameTNF superfamily member 12
NCBI Gene AliasesTWEAK, APO3L, TNLG4A, DR3LG
Purity>95%, by SDS-PAGE under reducing conditions and visualized by silver stain
Molecular Weight18.3 kDa
ApplicationsBioactivity
Conjugate/TagUnconjugated
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

(1) NIK/MAP3K14 in hepatocytes orchestrates NASH to hepatocellular carcinoma progression via JAK2/STAT5 inhibitionMolecular metabolismDecember 1, 2022Vesting AJ, Jais A, Klemm P, Steuernagel L, Wienand P, Fog-Tonnesen M, Hvid H, Schumacher AL, Kukat C, Nolte H, et al.

(2) Proteolytically generated soluble Tweak Receptor Fn14 is a blood biomarker for γ-secretase activityEMBO molecular medicineOctober 10, 2022Güner G, Aßfalg M, Zhao K, Dreyer T, Lahiri S, Lo Y, Slivinschi BI, Imhof A, Jocher G, Strohm L, et al.

(3) Evaluation of Computationally Designed Peptides against TWEAK, a Cytokine of the Tumour Necrosis Factor Ligand FamilyInternational journal of molecular sciencesJanuary 21, 2021Badia-Villanueva M, Defaus S, Foj R, Andreu D, Oliva B, Sierra A, Fernandez-Fuentes N.

(5) An anti-TL1A antibody for the treatment of asthma and inflammatory bowel diseasemAbsMay 1, 2018Clarke AW, Poulton L, Shim D, Mabon D, Butt D, Pollard M, Pande V, Husten J, Lyons J, Tian C, et al.

(6) NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosusNature communicationsJanuary 12, 2018Brightbill HD, Suto E, Blaquiere N, Ramamoorthi N, Sujatha-Bhaskar S, Gogol EB, Castanedo GM, Jackson BT, Kwon YC, Haller S, et al.

(8) TWEAK/Fn14 promotes pro-inflammatory cytokine secretion in hepatic stellate cells via NF-κB/STAT3 pathwaysMolecular immunologyJuly 1, 2017Wang A, Zhang F, Xu H, Xu M, Cao Y, Wang C, Xu Y, Su M, Zhang M, Zhuge Y.

(9) TWEAK mediates inflammation in experimental atopic dermatitis and psoriasisNature communicationsMay 22, 2017Sidler D, Wu P, Herro R, Claus M, Wolf D, Kawakami Y, Kawakami T, Burkly L, Croft M.

(12) Tumor Necrosis Factor-Like Weak Inducer of Apoptosis Activates Type I Interferon Signals in Lupus NephritisBioMed research internationalJanuary 1, 2017Xue L, Liu L, Huang J, Wen J, Yang R, Bo L, Tang M, Zhang Y, Liu Z.

(15) The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatmentThe Journal of investigative dermatologyApril 1, 2013Zhou H, Ekmekcioglu S, Marks JW, Mohamedali KA, Asrani K, Phillips KK, Brown SA, Cheng E, Weiss MB, Hittelman WN, et al.

Recombinant Human TWEAK/TNFSF12 Protein, CF